FDC Ltd has announced that the Company has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA), Timolol Maleate Ophthalmic Solution.
Timolol Maleate is a nonselective beta-blocking drug, used as a primary line of treatment for glaucoma.
The Company's other two ANDAs Ciprofioxacin Ophthalmic Solution and Ofloxacin Ophthalmic Solution are in the pipeline, in the final stages of approval. Besides these three ANDAs, FDC also has on its anvil around five more products at an advanced stage of filing.
FDC has also to its credit twelve DMF's (Drug Master Files) and ten Marketing Authorizations in UK.
The Stock closed on Friday at Rs.29.75, up by Rs.0.45 or 1.54%. The stock hit an intraday high of Rs.31.45 and low of Rs.28.70.
The total traded quantity was 150581 compared to 2 week average of 59038.
|
